XOMA ROYALTY CORP (XOMA)
Health Care · Biotech royalty aggregator / intellectual property financing · NASDAQ
A lean-infrastructure royalty aggregator that generates non-dilutive capital for biotech developers in exchange for long-duration milestone and royalty rights across a diversified 120+ asset portfolio spanning oncology, rare disease, and specialty therapeutics.
What XOMA ROYALTY CORP does
XOMA Royalty Corp is a royalty aggregator that acquires economic rights to future milestone and royalty payments from clinical-stage and approved pharmaceutical products in exchange for non-dilutive capital to drug developers. The company maintains a diversified portfolio of over 120 assets across therapeutic areas, anchored by seven commercial-stage assets including VABYSMO (for retinal diseases), OJEMDA (pediatric oncology), and MIPLYFFA (rare disease). It operates with a lean infrastructure where substantially all R&D and commercialization costs are borne by the asset sponsors, generating revenue primarily through royalty and milestone cash receipts.
Themes: ["Royalty aggregation / biotech financing","Clinical-stage therapeutics — milestone-driven payments","Oncology (immunotherapy / checkpoint inhibitors / pan-RAF inhibitors)","Rare disease","Retinal / ophthalmology","Women's health","Gene therapy","Pain management","Hematology (bleeding disorders)","Neonatology"]
Fundamentals
- Price$44.80 as of 2026-07-09 close
- Market cap$776M as of 2026-07-10
- 1-year return+61.7% as of 2026-07-09 close
- P/E22.95 as of 2026-07-10
- Net margin+69.6% as of 2026-07-10
- Gross margin+100.0% as of 2026-07-10
- ROE+32.4% as of 2026-07-10
- Debt / equity0.91 as of 2026-07-10
- Revenue growth (YoY)+13.2% as of 2026-07-10
- Revenue CAGR (3y)+105.3% SEC XBRL
- Beta0.88 as of 2026-07-10
Dividend: yield +0.7%; pays a dividend.
Key risks (from latest filing)
["Binary risk on individual assets: regulatory approval or development failure of licensed therapeutics would eliminate or materially reduce expected milestone and royalty payments, with no recourse to XOMA","Licensee funding constraints: third-party developers and sponsors may lack capital to continue development, delaying or halting programs in which XOMA has economic interests","Market and commercialization risk: even if approved, products may face market adoption challenges, restrictive marketing restrictions, regulatory withdrawal, or competitive obsolescence that reduce royalty streams"]
Competitors & peers
- Royalty Pharma (RPRX)
- Silvercrest Asset Management
- Cocrystal Pharma
- Lantern Pharma
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.